The impact of metabolic syndrome on the outcomes of transurethral resection of the prostate.
To investigate the effect of metabolic syndrome (MS) and its components on the outcomes of transurethral resection of the prostate (TURP). Fifty patients with MS and 50 without MS were enrolled for the study. Patients without MS were assigned to Group 1 and patients with MS were in Group 2. Patients were evaluated by the International Prostate Symptom Score (IPSS), Quality of Life index (QoL), maximum urine flow rate (Qmax), prostate-specific antigen level, and urinary ultrasonography. Six months after surgery, patients were again evaluated by IPSS and uroflowmetry; then comparison was made between the groups with respect to IPSS, QoL, and Qmax. Postoperative IPSS was determined as 11.2±0.87 in Group 1 and 12.9±0.88 in Group 2 (P<0.05). Postoperative Qmax values were determined as 18.2±0.81 and 13.9±1.12 for the two groups, respectively (P<0.05). After multivariate analyses, elevated fasting glucose (EFG) and dyslipidemia were determined to have a significant correlation with IPSS improvement. EFG and hypertension had a significant negative impact on Qmax, and hypertension and abdominal obesity had a significant correlation with QoL improvement. MS as a comorbidity seems to diminish the effects of TURP. Further well-designed prospective, randomized studies with larger cohorts are needed to confirm the findings of this study.